Home > Boards > US Listed > Medical - Drugs > Matinas Biopharma Hldgs, Inc. (MTNB)

Lypdiso is the brand name for MAT 9001,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
The Lawman Member Profile
Member Level 
Followed By 6
Posts 446
Boards Moderated 0
Alias Born 04/20/16
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/24/2021 5:31:08 PM
Matinas BioPharma to Hold Virtual R&D Day on June 17, 2021 GlobeNewswire Inc. - 5/20/2021 8:00:00 AM
Matinas Biopharma EPS and revenue in-line Seeking Alpha - 5/10/2021 6:40:37 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2021 6:32:06 AM
Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights GlobeNewswire Inc. - 5/10/2021 6:30:00 AM
Matinas BioPharma to Participate in 7th Annual Truist Securities Life Sciences Summit GlobeNewswire Inc. - 4/28/2021 7:30:00 AM
Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2021 Financial and Operational Results on May 10, 2021 GlobeNewswire Inc. - 4/27/2021 7:30:00 AM
Matinas BioPharma to Present at the Needham Healthcare Conference GlobeNewswire Inc. - 4/8/2021 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/5/2021 7:26:02 PM
Matinas Posts Quarterly Loss In-Line With Expectations TipRanks - 3/29/2021 8:53:01 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/29/2021 6:35:46 AM
Matinas Biopharma EPS in-line, misses on revenue Seeking Alpha - 3/29/2021 6:35:36 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/29/2021 6:33:26 AM
Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights GlobeNewswire Inc. - 3/29/2021 6:30:00 AM
Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results o... GlobeNewswire Inc. - 3/15/2021 7:00:00 AM
Matinas BioPharma to Present at the Barclays Global Healthcare Conference GlobeNewswire Inc. - 3/1/2021 7:30:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 2/26/2021 5:39:15 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 5:18:17 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 4:43:35 PM
Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa® GlobeNewswire Inc. - 2/1/2021 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/27/2021 5:29:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/14/2021 7:01:34 AM
Matinas BioPharma to Present at the ICR Conference 2021 GlobeNewswire Inc. - 1/6/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 6:31:02 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 6:30:56 PM
The Lawman Member Level  Monday, 01/11/21 11:57:02 AM
Re: None
Post # of 662 
Lypdiso is the brand name for MAT 9001, that is now in a second head to head trial vs. Vascepa, with topline results to be announced in 1Q 21. I expect such results to again show that MAT 9001 is far superior to Vascepra in lowering triglycerides, PCSK9, and various other lipid markers.

Also in the MTNB pipeline are (1) MAT 2203 (LNC version of amphotericin b), which is now in a Phase 2 trial for cryptococcal meningitis, fully funded and sponsored by the NIH, and (2) MAT 2205 (LNC version of amikacin), which has funding for research from the Cystic Fibrosis Foundation.

Of course, the LNC platform can potentially make many more effective, but highly toxic, drugs, safe and effective, which is why five big pharmaceutical companies are now in collaborations with MTNB to encochleate their drugs.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences